Genprex announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for a patent covering Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 or PD-L1 antibodies for non-small cell and small cell lung cancer. This patent strengthens the company's intellectual property portfolio, providing crucial protection for therapeutic combinations currently being evaluated in the Acclaim-3 clinical trial. This expands on previously granted patents for REQORSA in other major markets.

Soligenix, Inc. received a Nasdaq delisting notice for failing to meet the minimum bid price requirement, with 180 days to regain compliance. Concurrently, the company terminated its HyBryte™ development program for cutaneous T-cell lymphoma following a Phase 3 futility recommendation. Soligenix is now evaluating all strategic options, including M&A opportunities and advancing its other pipeline programs like dusquetide for Behçet’s Disease.

Fulcrum Therapeutics, Inc. has approved a restructuring plan, reducing its workforce by approximately 85% and incurring $4.2 million in charges, following the discontinuation of pociredir for sickle cell disease. Concurrently, Fulcrum has initiated a comprehensive review of strategic alternatives to maximize stockholder value, engaging Leerink Partners LLC as its financial advisor. Potential options include a merger, acquisition, business combination, or sale/licensing of assets.

Fulcrum Therapeutics, Inc. announced the discontinuation of its pociredir program, which was being developed for the treatment of sickle cell disease. Concurrently, the company initiated a comprehensive review of strategic alternatives aimed at maximizing stockholder value.

Genprex announced positive clinical data from its Acclaim trials for Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in lung cancer, presented at the 2026 ASCO Annual Meeting. The data showed that high Trop-2 levels and low PTEN levels correlated with prolonged Progression Free Survival (PFS) in Non-Small Cell Lung Cancer (NSCLC) patients treated with Reqorsa. These identified biomarkers may help predict patient response and enable targeted patient selection for precision medicine.

Genprex announced positive preclinical data for its diabetes gene therapy, GPX-002 (Pdx1/MafA gene therapy), presented at the ASGCT Annual Meeting. The data demonstrated that the therapy reversed hyperglycemia and improved beta-cell function and maturation in Type 2 diabetic mouse models. This preclinical success is considered a pivotal step towards a potentially transformative treatment for T2D, aiming for long-term glycemic control by directly addressing beta-cell dysfunction.